SEC Tracker
Get the app

BioNTech BNTX

BioNTech reports Q3 2026 results and corporate updates

Foreign issuer report

Form
6-K
Filed
Importance
Routine
  1. Third quarter 2026 revenues of €1,289.2 million
  2. Adjusted R&D expenses of €578.5 million
  3. Raised full-year 2026 revenue guidance to €1.7–1.9 billion
  4. Cash, cash equivalents, and security investments of €16.2 billion

Written from the 6-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when BioNTech files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Acumen Pharmaceuticals ABOS public float $45M, Jun 30, 2025
  2. Alpha Cognition ACOG public float $149M, Jun 30, 2025
  3. Adaptimmune Therapeutics ADAP
  4. Adma Biologics ADMA public float $4.2B, Jun 30, 2025
  5. Adaptive Biotechnologies ADPT public float $1.4B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.